Table 1 Demographic and clinical information.

From: Mitochondrial function in individuals at clinical high risk for psychosis

Demographics

 

Healthy controls (n = 16)

Clinical high risk (n = 27)

  

Age (years), SD

 

21.25 ± 2.05

20.26 ± 1.72

t = 1.70

p = 0.10

Gender

Male

5

15

χ2 = 2.39

p = 0.12

 

Female

11

12

  

BMI, SD

 

23.99 ± 5.00

23.94 ± 5.66

U = 212

p = 0.92

NNT, SD1

 

6643.56 ± 2598.70

6719.50 ± 2560.16

U = 207

p = 0.98

Drug use (current)2

Tobacco

0

7

χ2 = 4.96

p = 0.03

 

Cannabis

0

2

χ2 = 1.24

p = 0.27

 

None

16

20

  

Antipsychotic use3

 

0

5

  

   SOPS, SD

Total

 

35.70 ± 9.64

  
 

Positive

 

11.78 ± 3.38

  
 

Negative

 

10.78 ± 5.02

  
 

Disorganization

 

3.63 ± 2.31

  
 

General

 

8.48 ± 3.79

  

   RBANS, SD

Total

86.25 ± 13.97

88.89 ± 14.28

  
 

Immediate memory

94.88 ± 15.58

95.19 ± 15.36

  
 

Visuospatial memory

81.25 ± 21.20

85.52 ± 12.97

  
 

Language

84.94 ± 18.21

83.81 ± 21.68

  
 

Attention

97.94 ± 14.69

99.74 ± 17.03

  
 

Delayed memory

89.25 ± 13.48

93.81 ± 10.03

  
  1. Abbreviations: BMI, body mass index; NNT, nicotinamide nucleotide transhydrogenase; RBANS, Repeatable Battery for the Assessment of Neuropsychological Status; SD, standard deviation; SOPS, scale of psychosis-risk symptoms.
  2. 1One CHR was excluded from the mitochondrial complex function analysis due to unreliable values.
  3. 2All participants had a negative urine drug screen for cannabis, ethanol, methadone, and cocaine at baseline except two CHR who had a positive urine drug screen for cannabis.
  4. 3CHR were currently on antipsychotic treatment with 75 mg of Quetiapine, one with 0.5 mg and two with 1.0 mg of Risperidone and the last one with 5 mg Aripiprazole.
Back to article page